3 Beaten-Down Genomics Stocks: Can They Recover?
All three of these companies can test for COVID-19, but they're well-suited to produce steadier revenue in ways that have nothing to do with coronaviruses. Exact Sciences' (NASDAQ: EXAS) stock price has tumbled around 41% since its high watermark this February. Screening for cancer is this company's bread and butter, but rapidly rising COVID-19 testing revenue excited investors enough to drive the stock to new all-time highs earlier this year.